An Analysis of Regularity in Fasting Blood Sugar Variations and Influence Factors After Kidney Transplantation
Science Journal of Public Health
Volume 7, Issue 6, November 2019, Pages: 200-205
Received: Sep. 23, 2019;
Published: Nov. 18, 2019
Views 589 Downloads 172
Zhufu Shao, Department of Critical Care Medicine, Binzhou People's Hospital, Binzhou City, P. R. China
Ruirui Xu, Department of Nephrology, Binzhou People's Hospital, Binzhou City, P. R. China
Chunyan Yang, Department of Critical Care Medicine, Binzhou People's Hospital, Binzhou City, P. R. China
Objective To discuss the regularity in fasting blood sugar variations following kidneytransplantation and evaluate the PTDM morbidity and the effect of fasting blood sugar on survival and complications of patients. Method 422 patients receiving kidneytransplantation in our hospital from January 2015 to December 2018 were collected. Based on the pre-operative fasting blood sugar, the patients were divided into Group DM, IFG, and NFG. The variation trends of fasting blood sugar in various groups were obtained by analysing the fasting blood sugar data of patients 3, 6, 9, 12, 24, 36, 48, and 60 months before and after operation. The PTDM occurrence conditions were analysed 3, 6, 9, 12, 36, and 60 months after operation based on the fasting blood sugar of patients; a simplified OGTT was performed for patients with their fasting blood sugar not meeting the diagnostic criteria for diabetes ≥3 years after kidneytransplantation to analyse the PTDM morbidity among patients ≥3 years after kidneytransplantation and calculate the HOMA index. The patients were divided into Group DM, IFG, and NFG based on fasting blood sugar before kidneytransplantation and PTDM Group and Non-PTDM Group. A comparison was made for the difference in survival rate among various groups. Result The fasting blood sugar in the Group DM decreased significantly compared with that before operation (P<0.05); the fasting blood sugar in the Group IFG and NFG increased compared that before operation (P<0.05). The PTDM morbidity exhibited an overall decreasing trend with time and reached as high as 52.82% 3 months after operation. HOMA-IR was the highest in Group IGR followed by Group PTDM. HOMA-IR significantly increased in Group IGR compared with the group of normal blood sugar (P<0.05). HOMA-β in Group PTDM decreased significantly compared with the group of normal blood sugar and Group IGR (P<0.05). The survival rate in Group DM significantly decreased compared with that in Group NFG (P<0.05); the survival rate in Group IFG also decreased significantly compared with that in Group NFG (P<0.05); the average survival time and survival rate in Group PTDM were significantly lower than those in groups other than Group PTDM (P<0.05). Conclusion kidneytransplantation is able to improve the fasting blood sugar of patients with diabetes and the blood sugar can significant affect the survival rate of kidneytransplantation patients and lower the survival rate of patients.
An Analysis of Regularity in Fasting Blood Sugar Variations and Influence Factors After Kidney Transplantation, Science Journal of Public Health.
Vol. 7, No. 6,
2019, pp. 200-205.
Borda B. Lengyel C. et al. Post-transplant diabetes mellitus - risk factors and effects on the function and morphology of the allograft [J]. Acta Physiol Hung, 2019, 99 (2): 206-15.
Ali IH. Abderrahim E. et al. Morbidity and mortality in Tunisian patients with post-transplant diabetes mellitus [J]. Saudi J Kidney Dis Transpl, 2018, 24 (3): 583-6.
Xu Y. Liang JX. et al. Prevalence and long-term glucose metabolism evolution of post-transplant diabetes mellitus in Chinese renal recipients [J]. Diabetes Res Clin Pract, 2018, 92 (1): 11-8.
Choi JY. Kwon OJ. Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants?[J]. Transplant Proc, 2018, 45 (8): 2892-8.
Courivaud C. Ladriere M. et al. Impact of pre-transplant dialysis modality on post-transplant diabetes mellitus after kidney transplantation [J]. Clin Transplant, 2018, 25 (5): 794-9.
Madziarska K. Weyde W. et al. The increased risk of post-transplant diabetes mellitus in peritoneal dialysis-treated kidney allograft recipients [J]. Nephrol Dial Transplant, 2018, 26 (4): 1396-401.
Dutkiewicz G. Domanski L. et al. Polymorphisms of superoxide dismutase, glutathione peroxidase and catalase genes in patients with post-transplant diabetes mellitus [J]. Arch Med Res, 2018, 41 (5): 350-5.
Niu YJ. Shen ZY. et al. Establishment of tacrolimus-induced diabetes in rat model and assessment of clinical treatments for post-transplant diabetes mellitus in kidneytransplant recipients [J]. Clin Lab, 2018, 59 (7): 869-74.
Saemann MD. Krebs M. Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option? [J]. Wien Klin Wochenschr, 2017, 122 (7): 198-202.
Demirci MS. Toz H. et al. Risk factors and consequences of post-transplant diabetes mellitus [J]. Clin Transplant, 2017, 24 (5): 170-7.
Haider DG. Mittermayer F. et al. Postprandial blood glucose level in maintenance hemodialysis patients predicts post-transplant-diabetes-mellitus [J]. Exp Clin Endocrinol Diabetes, 2017, 118 (3): 200-4.
Gomes MB. Cobas RA. et al. Post-transplant diabetes mellitus [J]. Diabetol Metab Syndr, 2019, 1 (1): 14-9.
Bayes B. Moreso F. et al. Post-transplant diabetes mellitus depending on the pre-transplant dialysis technique [J]. Nefrologia, 2018, 28 (6): 97-102.
Hathout E. Alonso E. et al. Post-transplant diabetes mellitus in pediatric kidneytransplantation [J]. Pediatr Transplant, 2019, 13 (5): 599-605.
Xu X. Ling Q. et al. Post-transplant diabetes mellitus in kidneytransplantation: Hangzhou experience [J]. Hepatobiliary Pancreat Dis In, 2018, 7 (5): 465-70.
Fabrizi F. Messa P. et al. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis [J]. Int J Artif Organs, 2018, 31 (8): 675-82.
Ollech JE. Kramer MR. et al. Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors [J]. Eur J Cardiothorac Surg, 2018, 33 (5): 844-8.
Leung Ki EL. Venetz JP. et al. Cytomegalovirus infection and new-onset post-transplant diabetes mellitus [J]. Clin Transplant, 2017, 22 (2): 245-9.
Pietrzak-Nowacka M. Safranow K. et al. Autosomal dominant polycystic kidney disease is not a risk factor for post-transplant diabetes mellitus. Matched-pair design multicenter study [J]. Arch Med Res, 2017, 39 (3): 312-9.
Soliman AR. Fathy A. et al. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant [J]. Exp Clin Transplant, 2018, 11 (6): 494-8.
Elens L. Sombogaard F. et al. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-alpha are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus [J]. Pharmacogenet Genomics, 2018, 23 (12): 649-57.
Bonet J. Martinez-Castelao A. et al. Metabolic syndrome in hemodialysis patients as a risk factor for new-onset diabetes mellitus after renal transplant: a prospective observational study [J]. Diabetes Metab Syndr Obes, 2018, 6: 339-46.
Balgradean M. Cinteza E. et al. Post renal transplant type 2 diabetes mellitus in a case of familial juvenile nephrophthisis [J]. Maedica (Buchar), 2018, 8 (1): 26-9.
Lankarani KB. Eshraghian A. et al. New Onset Diabetes and Impaired Fasting Glucose After kidneyTransplant: Risk Analysis and the Impact of Tacrolimus Dose [J]. Exp Clin Transplant, 2018, 7 (30): 591-6.
Dukes JL. Seelam S. et al. Health-related quality of life in kidney transplant patients with diabetes [J]. Clin Transplant, 2018, 27 (5): 554-62.
Veroux M. Tallarita T. et al. Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation [J]. Clin Dev Immunol, 2018, 6: 526-30.
Dostalek M. Sam WJ. et al. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human kidneymicrosomes [J]. Clin Pharmacokinet, 2019, 51 (9): 591-606.
Lorho R. Hardwigsen J. et al. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in kidneytransplant patients: results of a pilot study [J]. Clin Res Hepatol Gastroenterol, 2018, 35 (6): 482-8.
Gallagher EJ. Courgi R. et al Resolution of insulin-requiring diabetes in a kidneytransplant recipient after treatment of a pheochromocytoma: case report and review of literature.[J]. Minerva Endocrinol, 2018, 36 (4): 341-5.
Veldt BJ. Duarte-Rojo A. et al. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in kidneytransplant patients with chronic hepatitis C [J]. Am J Transplant, 2019, 12 (3): 737-44.